8-K: Alkermes to Acquire Avadel for $2.1B, Boosting Sleep Medicine Portfolio

Alkermes plc announced a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $2.1 billion, including a contingent value right, to expand its commercial presence in the sleep medicine market with LUMRYZ.

Summary

• Alkermes plc will acquire Avadel Pharmaceuticals plc for total consideration of up to $20.00 per share.
• The transaction values Avadel at approximately $2.1 billion on a fully diluted basis, assuming the contingent value right (CVR) payment is made.
• The consideration includes $18.50 per share in cash at closing.
• An additional non-transferable CVR of $1.50 per share is contingent upon final FDA approval of LUMRYZ for the treatment of idiopathic hypersomnia in adults and the dismissal of specific legal claims by December 31, 2028.
• The acquisition is expected to close in the first quarter of 2026, subject to regulatory and Avadel shareholder approvals.
• LUMRYZ (sodium oxybate), Avadel's FDA-approved product for narcolepsy, will be added to Alkermes' commercial portfolio.
• Avadel reported expected net revenues of $265 $275 million for 2025.
• Approximately 3,100 patients were on LUMRYZ therapy as of June 30, 2025.
• LUMRYZ new patient starts outpaced the twice-nightly mixed-salts competitor by more than 2:1 since July 2023.
• The transaction is expected to be immediately accretive and enhance Alkermes' revenue growth and profitability upon closing.
• Alkermes plans to finance the acquisition with cash on hand, supplemented by a fully underwritten bridge term loan credit facility of up to $1.23 billion from JPMorgan Chase Bank, N.A.
• The acquisition has been unanimously approved by the boards of directors of both companies.

Sentiment

Score: 8

Explanation: The acquisition offers significant strategic and financial benefits for Alkermes, including immediate accretion, diversification, and accelerated market entry, despite the contingent nature of part of the consideration and inherent risks in drug development. The substantial premium for Avadel shareholders and the resolution of key litigation are also positive indicators.

Positives

• Augments Alkermes' revenue growth profile and diversifies its commercial portfolio with LUMRYZ, a high-growth product.
• Accelerates Alkermes' commercial entry into the sleep medicine market and provides a strong foundation for the potential launch of alixorexton.
• Expected to be immediately accretive and enhance Alkermes' profitability upon closing.
• Positions the combined organization to accelerate innovation and expand leadership in treatments for sleep disorders and other neurological disorders.
• Drives operational efficiencies and synergies as Alkermes prepares for alixorexton's potential commercial launch.
• Expands the development pipeline in sleep disorders, including ALKS 4510, ALKS 7290, and valiloxybate.
• LUMRYZ has demonstrated strong market uptake with approximately 3,100 patients on therapy as of June 30, 2025.
• LUMRYZ new patient starts outpaced the twice-nightly mixed-salts competitor by more than 2:1 since July 2023.
• LUMRYZ has patent protection into 2042.
• Avadel achieved profitability and positive cash flow in Q2 2025.
• Alkermes has a strong balance sheet with $1.14 billion of cash and total investments as of September 30, 2025.
• The acquisition price represents a premium of approximately 38% to Avadel's weighted average trading price over the three months prior to announcement (assuming CVR payout).
• The acquisition price represents a premium of approximately 12% to Avadel's closing price on October 21, 2025 (assuming CVR payout).
• The settlement of ongoing litigation with Jazz Pharmaceuticals, Inc. on October 21, 2025, positively impacts Avadel's valuation.

Negatives

• The contingent value rights (CVRs) are complex instruments, and there is no certainty the Milestone will occur or that any payment will be made; if the Milestone is not achieved by December 31, 2028, the CVRs will have no value.
• No cash confirmation exercise has been undertaken by Alkermes to verify resources for CVR payments, placing CVR holders at risk if resources are unavailable.
• Potential for significant changes in transaction costs and/or unknown or inestimable liabilities and potential litigation associated with the planned acquisition.
• Adverse effects on the market price of Alkermes or Avadel ordinary shares and/or operating results as a result of the announcement or any inability to complete the acquisition.
• The announcement or pendency of the planned acquisition could result in disruption to the business and make it more difficult to maintain business and operational relationships of Alkermes and Avadel, including attracting and retaining qualified personnel.
• There is a possibility that competing offers may be made for Avadel.
• Clinical development activities for pipeline candidates may not be initiated or completed on expected timelines or at all, or results may not be positive or predictive of future real-world results.
• Products or product candidates could be shown to be ineffective or unsafe, or regulatory authorities may make adverse decisions.
• There is a risk of reduction in payment rate or reimbursement for products or an increase in related financial obligations to government payers.

Risks

• Uncertainty regarding the achievement of the CVR Milestone, which requires both FDA approval of LUMRYZ for idiopathic hypersomnia and the dismissal of specific legal claims by December 31, 2028.
• Potential for significant changes in transaction costs and/or unknown or inestimable liabilities and potential litigation associated with the planned acquisition.
• Adverse effects on the market price of Alkermes or Avadel ordinary shares and/or operating results due to the announcement or inability to complete the acquisition.
• Disruption to business and difficulty in maintaining business and operational relationships of Alkermes and Avadel, including attracting and retaining qualified management and other clinical and scientific personnel.
• Possibility of competing offers for Avadel.
• Clinical development activities (e.g., alixorexton, valiloxybate, LUMRYZ label expansion) may not be initiated or completed on expected timelines or at all, or results may not be positive or predictive of future real-world results.
• Products or product candidates could be shown to be ineffective or unsafe, or FDA or other regulatory authorities may not agree with regulatory approval strategies or make adverse decisions regarding products.
• Inability to successfully commercialize products or support revenue growth.
• Reduction in payment rate or reimbursement for products or an increase in related financial obligations to government payers.
• Products may prove difficult to manufacture, be precluded from commercialization by third-party proprietary rights, or have unintended side effects, adverse reactions, or incidents of misuse.
• General economic, political, market, and business conditions, or future exchange and interest rates, changes in tax laws, regulations, rates, and policies may negatively impact the combined organization.
• The CVRs are contractual rights only, non-transferable except under limited circumstances, not certificated or registered with the SEC or listed for trading, and do not have voting or dividend rights or represent equity/ownership interest.
• No assurance that the Milestone will be achieved prior to the Milestone Expiration or termination of the CVR Agreement, or that any payment will be required of Alkermes.

Future Outlook

Alkermes expects the acquisition to be immediately accretive and enhance its revenue growth profile and profitability upon closing in Q1 2026. The combined organization's financial strength will support a broad development strategy for Alkermes' orexin 2 receptor agonists (ALKS 4510, ALKS 7290) and potential label expansion for LUMRYZ in idiopathic hypersomnia, as well as advancement of valiloxybate. Integration of Avadel's operations is expected to drive cost synergies and operational efficiencies.

Management Comments

• Richard Pops, Chief Executive Officer of Alkermes: "This transaction represents a pivotal step in Alkermes strategic evolution. With the acquisition of Avadel, we are able to accelerate our commercial entry into the sleep medicine market at a critical inflection point as we prepare to advance alixorexton into a phase 3 program in narcolepsy. Avadel's innovative portfolio, commercial capabilities and dedicated employees provide a strong foundation for growth in this therapeutic area. Enabled by our strong balance sheet, this all-cash transaction enhances our revenue growth profile and is expected to be immediately accretive, reinforcing our commitment to delivering long-term value for shareholders."
• Greg Divis, Chief Executive Officer of Avadel: "This transaction represents a compelling outcome for our shareholders and a powerful validation of our strategy, execution, commercial capabilities and the differentiated value of LUMRYZ. We've built a company deeply committed to transforming the lives of people living with narcolepsy, and I'm incredibly proud of what our team has accomplished. Alkermes shares our passion for innovation and patient impact and, together, we will continue this important work on behalf of people living with central disorders of hypersomnolence."

Industry Context

The acquisition positions Alkermes as a key player in the commercial sleep medicine market, accelerating its entry into this therapeutic area. This move is strategic as Alkermes prepares to advance its own orexin 2 receptor agonist, alixorexton, into Phase 3 for narcolepsy, leveraging Avadel's established commercial infrastructure and rare disease experience. The combined entity aims to expand leadership in treatments for sleep disorders and other neurological disorders, supporting a broader development strategy for its pipeline candidates.

Comparison to Industry Standards

• LUMRYZ new patient starts outpaced the twice-nightly mixed-salts competitor by more than 2:1 since July 2023, indicating strong market acceptance and differentiation.
• Approximately 40% of eligible patients state middle-of-the-night dosing is a main reason they have not tried a twice-nightly oxybate, highlighting LUMRYZ's once-at-bedtime advantage over existing treatments.
• Over 90% of providers who had never prescribed an oxybate agree that middle-of-the-night dosing is a challenge, further validating LUMRYZ's differentiated profile.
• Approximately 94% of patients who switched from first-generation oxybate prefer LUMRYZ.

Management Changes

Corporate Governance

Legal Proceedings

• Dismissal of claims with prejudice by the United States District Court for the District of Delaware in cases: Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, C.A. No. 21-00691; Jazz Pharmaceuticals, Inc. et al v. Avadel CNS Pharmaceuticals, LLC, C.A. No. 21-01138; Jazz Pharmaceuticals, Inc. et al v. Avadel CNS Pharmaceuticals, LLC, C.A. No. 21-01594; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al, C.A. No. 22-00487; Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc., C.A. No. 22-00941; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al, C.A. No. 25-00009; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al, C.A. No. 25-00057; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc., et al, C.A. No. 25-00221; and Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al, C.A. No. 25-00435. This dismissal is a condition for the CVR Milestone.
• Avadel accepted a non-binding proposal to settle its litigation with Jazz Pharmaceuticals, Inc. on October 16, 2025, which was subsequently memorialized in a binding settlement agreement on October 21, 2025.

Related Party Transactions

• The Bridge Term Loan Credit Agreement refers to 'transactions with Affiliates as set forth on Schedule 6.07', but this schedule is not provided in the filing. No specific related party transactions are detailed in the main filing text.

Stakeholder Impact

• Shareholders (Avadel): Will receive $18.50 cash per share and a CVR for a potential additional $1.50 per share, representing a significant premium. Will need to approve the Scheme.
• Shareholders (Alkermes): Expected to benefit from immediate accretion, enhanced revenue growth, and profitability, and expanded leadership in sleep disorders.
• Employees (Avadel): Alkermes recognizes their skills and contributions. Existing employment rights, including pension rights, will be safeguarded. Some operational and administrative reorganization is anticipated, potentially affecting central corporate and support functions, but no decisions on specific roles or locations have been made.
• Customers/Patients: Expected to benefit from accelerated innovation and expanded leadership in treatments for sleep disorders. LUMRYZ's differentiated profile and potential label expansion, along with other pipeline candidates, aim to address unmet needs.
• Creditors (Alkermes): The Bridge Term Loan Credit Facility provides financing, and the company's financial health is expected to improve post-acquisition.

Next Steps

• Closing of the acquisition in Q1 2026, subject to regulatory approvals and Avadel shareholder approvals.
• Final FDA approval of LUMRYZ for idiopathic hypersomnia in adults by December 31, 2028, for CVR payout.
• Advancing alixorexton into a Phase 3 program in narcolepsy.
• Further development of ALKS 4510 and ALKS 7290 (currently in Phase 1 studies).
• Advancement of clinical studies for potential label expansion opportunities for LUMRYZ (Phase 3 in idiopathic hypersomnia).
• Potential advancement of valiloxybate (in-licensed salt-free, once-at-bedtime oxybate candidate).
• Integration planning and review of Avadel's business by Alkermes' senior management.
• Evaluation of consolidation of Avadel's business locations, including U.S. headquarters, into Alkermes' global headquarters in Dublin, Ireland, and other U.S. locations.
• Delisting of Avadel shares from Nasdaq Global Market and deregistration under the Exchange Act after the Effective Time.
• Avadel shareholders to vote on the Scheme Meeting Resolution and Required EGM Resolutions.
• High Court sanction of the Scheme.
• Filing of the Court Order with the Registrar of Companies.

Key Dates

Recommendation

The acquisition of Avadel by Alkermes is strategically sound, immediately accretive, and offers significant growth potential in the sleep medicine market. The premium paid to Avadel shareholders is substantial, and the CVR provides additional upside tied to a clear regulatory milestone. Alkermes' strong financial position and existing commercial infrastructure are well-suited to maximize the value of LUMRYZ and advance the combined pipeline. The settlement of prior litigation also de-risks Avadel's core asset. This transaction positions Alkermes for enhanced long-term value creation.

Keywords

Alkermes, Avadel, Acquisition, Biopharmaceutical, Sleep Medicine, LUMRYZ, Narcolepsy, Idiopathic Hypersomnia, FDA Approval, CVR, Orexin Agonist, ALKS 4510, ALKS 7290, Valiloxybate, Pharmaceutical M&A, SEC Filing